Substituted .alpha.-methylbenzyl and tricyclic arylalkyl lactamimides as inhibitors of blood platelet aggregation

Publisher Website
Google Scholar
Abstract
N-[1-(p-Phenoxyphenyl)ethyl]hexahydro-2H-azepin-2-imine hydrochloride and N-[1-(2-dibenzothienyl)-ethyl]hexahydro-2H-azepin-2-imine hydrochloride inhibited in vitro aggregation of human blood platelets induced by ADP with minimal release of procoagulant platelet factor 3. The compounds were selected from a series of substituted .alpha.-methylbenzyl and tricyclic arylalkyl lactamimides that were free of hypoglycemic and diuretic effects. N-[1-(1-naphthyl)ethyl]hexahydro-2H-azepin-2-imine hydrochloride and N-(2,2-diphenylpentyl)hexahydro-2H-azepin-2-imine hydrochloride, were also evaluated for effects on ADP-induced platelet aggregation after repeated oral administration to guinea pigs. RMI 12,366A showed in vivo activity in this system 2 h after the last of 4 daily doses of 100 mg/kg orally.